PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity

AIDS

Volumn 21, Issue 4, 2007, Pages 467-476

  Keller, Marla J ^a   Guzman, Esmeralda ^a   Hazrati, Ehsan ^a   Kasowitz, Andrea ^a   Cheshenko, Natalia ^a   Wallenstein, Sylvan ^a   Cole, Amy L ^c   Cole, Alexander M ^c   Profy, Albert T ^b   Wira, Charles R ^d   Hogarty, Kathleen ^a   Herold, Betsy C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Indevus Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF CENTRAL FLORIDA   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Cytokines; Defensins; Genital herpes; HIV; Innate immunity; Microbicides

Indexed keywords

BETA DEFENSIN 2; CHEMOKINE; CYTOKINE; DEFENSIN; IMMUNOGLOBULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MICROBICIDE; ORAL CONTRACEPTIVE AGENT; PLACEBO; PRO 2000;

ABSTINENCE; ADULT; ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESCHERICHIA COLI; FEMALE; GYNECOLOGIC DISEASE; HOST RESISTANCE; HUMAN; INFECTION PREVENTION; INFLAMMATION; MENSTRUAL CYCLE; MUCOSAL IMMUNITY; NORMAL HUMAN; ORAL CONTRACEPTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS; UTERINE CERVIX CYTOLOGY;

ADMINISTRATION, INTRAVAGINAL; ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS, LOCAL; ANTIVIRAL AGENTS; CHEMOKINES; CYTOKINES; DEFENSINS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HERPES GENITALIS; HIV INFECTIONS; HUMANS; IMMUNITY, MUCOSAL; INFLAMMATION MEDIATORS; IRRIGATION; MIDDLE AGED; NAPHTHALENESULFONATES; POLYMERS; VAGINA; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 33847018110     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328013d9b5     Document Type: Article

References (32)

1. Van Damme L, Niruthisard S, Atisook R, Boer K, Dally L, Laga M, et al. Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection. AIDS 1998; 12:433-437.
2. Van Damme L, Chandeying V, Ramjee G, Rees H, Sirivongrangson P, Laga M, Perriens J. Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers. COL-1492 Phase II Study Group. AIDS 2000; 14:85-88.
3. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002; 360:971-977.
4. Fichorova RN, Tucker LD, Anderson DJ. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis 2001; 184:418-428.
5. Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 2002; 13:323-340.
6. Goletti D, Kinter AL, Hardy EC, Poli G, Fauci AS. Modulation of endogenous IL-1 beta and IL-1 receptor antagonist results in opposing effects on HIV expression in chronically infected monocytic cells. J Immunol 1996; 156:3501-3508.
7. Granowitz EV, Saget BM, Wang MZ, Dinarello CA, Skolnik PR. Interleukin 1 induces HIV-1 expression in chronically infected U1 cells: blockade by interleukin 1 receptor antagonist and tumor necrosis factor binding protein type 1. Mol Med 1995; 1:667-677.
8. Lore K, Sonnerborg A, Olsson J, Patterson BK, Fehniger TE, Perbeck L, Andersson J. HIV-1 exposed dendritic cells show increased pro-inflammatory cytokine production but reduced IL-1ra following lipopolysaccharide stimulation. AIDS 1999; 13:2013-2021.
9. Lazdins JK, Klimkait T, Woods-Cook K, Walker M, Alteri E, Cox D, et al. In vitro effect of transforming growth factor-beta on progression of HIV-1 infection in primary mononuclear phagocytes. J Immunol 1991; 147:1201-1207.
10. Moriuchi M, Moriuchi H. Cell-type-dependent effect of transforming growth factor beta, a major cytokine in breast milk, on human immunodeficiency virus type 1 infection of mammary epithelial MCF-7 cells or macrophages. J Virol 2004; 78:13046-13052.
11. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 1995; 96:456-464.
12. John M, Keller MJ, Fam EH, Cheshenko N, Hogarty K, Kasowitz A, et al. Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J Infect Dis 2005; 192:1731-1740.
13. Chang TL, Francois F, Mosoian A, Klotman ME. CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibition. J Virol 2003; 77:6777-6784.
14. Quinones-Mateu ME, Lederman MM, Feng Z, Chakraborty B, Weber J, Rangel HR, et al. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS 2003; 17:F39-F48.
15. Wang W, Owen SM, Rudolph DL, Cole AM, Hong T, Waring AJ, et al. Activity of alpha- and theta-defensins against primary isolates of HIV-1. J Immunol 2004; 173:515-520.
16. Yasin B, Wang W, Pang M, Cheshenko N, Hong T, Waring AJ, et al. Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry. J Virol 2004; 78:5147-5156.
17. Cheshenko N, Keller MJ, MasCasullo V, Jarvis GA, Cheng H, John M, et al. Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob Agents Chemother 2004; 48:2025-2036.
18. Scordi-Bello IA, Mosoian A, He C, Chen Y, Cheng Y, Jarvis GA, et al. Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob Agents Chemother 2005; 49:3607-3615.
19. Mauck CK, Baker JM, Birnkrant DB, Rowe PJ, Gabelnick HL. The use of colposcopy in assessing vaginal irritation in research. AIDS 2000; 14:2221-2227.
20. Keller MJ, Zerhouni-Layachi B, Cheshenko N, John M, Hogarty K, Kasowitz A, et al. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a doubleblind placebo-controlled trial. J Infect Dis 2006; 193:27-35.
21. Venkataraman N, Cole AL, Svoboda P, Pohl J, Cole AM. Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J Immunol 2005; 175:7560-7567.
22. Spear GT, al-Harthi L, Sha B, Saarloos MN, Hayden M, Massad LS, et al. A potent activator of HIV-1 replication is present in the genital tract of a subset of HIV-1-infected and uninfected women. AIDS 1997; 11:1319-1326.
23. Al-Harthi L, Spear GT, Hashemi FB, Landay A, Sha BE, Roebuck KA. A human immunodeficiency virus (HIV)-inducing factor from the female genital tract activates HIV-1 gene expression through the kappaB enhancer. J Infect Dis 1998; 178:1343-1351.
24. Hillier SL, Moench T, Shattock R, Black R, Reichelderfer P, Veronese F. In vitro and in vivo: the story of nonoxynol 9. J Acquir Immune Defic Syndr 2005; 39:1-8.
25. Boniotto M, Jordan WJ, Eskdale J, Tossi A, Antcheva N, Crovella S, et al. Human beta-defensin 2 induces a vigorous cytokine response in peripheral blood mononuclear cells. Antimicrob Agents Chemother 2006; 50:1433-1441.
26. Voss E, Wehkamp J, Wehkamp K, Stange EF, Schroder JM, Harder J. NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J Biol Chem 2006; 281:2005-2011.
27. Schaefer TM, Fahey JV, Wright JA, Wira CR. Innate immunity in the human female reproductive tract: antiviral response of uterine epithelial cells to the TLR3 agonist poly(I:C). J Immunol 2005; 174:992-1002.
28. Usala SJ, Usala FO, Haciski R, Holt JA, Schumacher GF. IgG and IgA content of vaginal fluid during the menstrual cycle. J Reprod Med 1989; 34:292-294.
29. Shrier LA, Bowman FP, Lin M, Crowley-Nowick PA. Mucosal immunity of the adolescent female genital tract. J Adolesc Health 2003; 32:183-186.
30. Hazrati E, Galen B, Lu W, Wang W, Ouyang Y, Keller MJ, et al. Human {alpha}- and beta-defensins block multiple steps in herpes simplex virus infection. J Immunol 2006; 177:8658-8666.
31. Valore EV, Park CH, Igreti SL, Ganz T. Antimicrobial components of vaginal fluid. Am J Obstet Gynecol 2002; 187:561-568.
32. Lacey CJ, Wright A, Weber JN, Profy AT. Direct measurement of in-vivo vaginal microbicide levels of PRO 2000 achieved in a human safety study. AIDS 2006; 20:1027-1030.